dronedarone

11/01/2004 - "Two recent studies on the prevention of atrial fibrillation have demonstrated that dronedarone is moderately effective with an excellent general tolerance."
01/01/2009 - "Furthermore, dronedarone, a prototypic multichannel blocker with additional effects on ventricular myocardium, has proven well tolerated and effective in the treatment of atrial fibrillation and may even reduce cardiovascular mortality. "
01/01/2010 - "The ATHENA trial demonstrated a significant reduction in cardiovascular hospitalizations and death in atrial fibrillation patients randomly assigned to receive dronedarone or placebo. "
03/01/2010 - "In two design-identical randomised clinical trials (EURIDIS and ADONIS trial) the efficacy of dronedarone to maintain sinus rhythm in patients with chronic atrial fibrillation/flutter was shown to be clearly superior to placebo. "
08/01/2012 - "Dronedarone on top of SOC appears to be a cost-effective treatment for atrial fibrillation compared with SOC alone. "

06/01/2010 - "Clinical studies have shown that dronedarone effectively reduces ventricular rate, may prevent or delay the recurrence of AF, and may reduce cardiovascular morbidity and mortality in patients with AF or atrial flutter. "
09/01/2009 - "Phase III clinical trials have shown dronedarone to be effective at reducing ventricular rate, reducing recurrence of AF, and reducing cardiovascular morbidity and mortality in patients with AF or atrial flutter (AFL). "
08/20/2009 - "Oral dronedarone was generally well tolerated in the treatment of adult patients with AF and/or atrial flutter in clinical studies. "
08/20/2009 - "Dronedarone exhibited rate- and rhythm-controlling properties in patients with atrial fibrilation (AF) or atrial flutter, significantly reducing the risk of a first recurrence of AF versus placebo following 12 months' therapy in the ADONIS and EURIDIS studies. "
05/01/2013 - "In conclusion, dronedarone is associated with frequent adverse events and moderate antiarrhythmic efficacy requiring discontinuation in most patients within the first 9 months of use, and there is a prevalent reversal from persistent to paroxysmal but also from paroxysmal to persistent atrial arrhythmias and from AF to non-isthmus-dependent atrial flutter."

10/01/2009 - "Conversely, the recently published ATHENA study (including more than 4,600 high risk patients, but excluding those with severe heart failure) demonstrated a significant reduction in cardiovascular hospitalizations and cardiovascular mortality with dronedarone compared to placebo. "
01/01/2008 - "[Efficacy of dronedarone in cardiac failure due to severe left ventricular systolic dysfunction. "
08/01/2013 - "In the ATHENA trial, dronedarone was used in elderly high risk patients with paroxysmal or persistent AF/AFl, excluding those with advanced heart failure, cardiovascular hospitalizations were significantly reduced. "
08/01/2013 - "In the ANDROMEDA trial, dronedarone treatment increased mortality and cardiovascular hospitalizations patients with decompensated heart failure. "
08/15/2012 - "Intervention was dronedarone for AF for some studies and heart failure for others. "

01/01/2010 - "Secondly, according to a post hoc analysis a significant reduction in stroke was observed (annual rate 1.2% on dronedarone vs 1.8% on placebo, respectively [hazard ratio 0.66, confidence interval 0.46 to 0.96, P = 0.027]). "
12/01/2011 - "Since smaller cerebral infarcts are sometimes asymptomatic, the reduced incidence of stroke might reflect reduction of infarct size (IS) by dronedarone. "
01/01/2015 - "None of them found any significant difference with the exception of a single trial than found less strokes in the group treated with dronedarone compared to placebo. "
12/01/2011 - "In the random effects model, the statistical weight of the ATHENA trial was much lower (45.1%) and the RD for stroke or TIA between the dronedarone and the placebo groups did not reach statistical significance (RD -0.0064, 95% CI -0.0144, 0.0016; p = 0.120). "
12/01/2011 - "The RD of the incidence of stroke or TIA in all trials between patients randomized to dronedarone and those randomized to placebo was -0.0094 (95% confidence interval [CI] -0.0178, -0.0011; p = 0.027). "

02/01/2011 - "Dronedarone was effective in completely suppressing ventricular tachycardia. "
03/01/2012 - "Dronedarone for recurrent ventricular tachycardia: a real alternative?"
02/01/2011 - "Suppression of ventricular tachycardia with dronedarone: a case report."
02/01/2011 - "A patient with recurrent atrial fibrillation and monomorphic ventricular tachycardia treated successfully with dronedarone."
03/01/2012 - "We report on a patient with non-ischemic dilated cardiomyopathy and recurrent ventricular tachycardia resistant to multiple antiarrhytmic agents, in whom dronedarone was effective in completely suppressing ventricular tachycardia episodes."